Lineage Cell Therapeutics Q2 EPS $(0.13) Misses $(0.03) Estimate, Sales $2.765M Beat $1.472M Estimate

Author: Benzinga Newsdesk | August 12, 2025 03:02pm
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.03) by 348.28 percent. This is a 333.33 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $2.765 million which beat the analyst consensus estimate of $1.472 million by 87.80 percent. This is a 96.38 percent increase over sales of $1.408 million the same period last year.

Posted In: LCTX